-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fs7bvJVpmiNzBDXFJyxMV+2GT3NaKbSaN9b1FbsWPrgLhSo51gks2U9nTcN+FqRj oV9H8gaWVjcJz27qaiwFyQ== 0001209191-10-000372.txt : 20100104 0001209191-10-000372.hdr.sgml : 20100101 20100104181446 ACCESSION NUMBER: 0001209191-10-000372 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091231 FILED AS OF DATE: 20100104 DATE AS OF CHANGE: 20100104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLOAN GAIL A CENTRAL INDEX KEY: 0001237523 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 10503555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2009-12-31 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001237523 SLOAN GAIL A 4365 EXECUTIVE DRIVE, SUITE 300 SAN DIEGO CA 92121 0 1 0 0 VP of Finance Restricted Stock Units 2009-12-31 4 A 0 483810 0.00 A Common Stock 483810 483810 D Each restricted stock unit represents a contingent right to receive one share of La Jolla Pharmaceutical Company common stock; award date value of common stock was $0.158 per share (the average of the closing prices of La Jolla Pharmaceutical Company's common stock for the five trading days following December 22, 2009). The restricted stock units vest upon the closing of La Jolla Pharmaceutical Company's proposed merger with Adamis Pharmaceuticals Corporation, subject to the continued employment of the reporting person through the closing date of the merger. /s/ Gail A. Sloan 2010-01-04 -----END PRIVACY-ENHANCED MESSAGE-----